These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 8118590)

  • 1. Progress in immunosuppression.
    Dunning J; Wallwork J
    Adv Card Surg; 1994; 5():141-61. PubMed ID: 8118590
    [No Abstract]   [Full Text] [Related]  

  • 2. Left ventricular dysfunction after heart transplantation: incidence and role of enhanced immunosuppression.
    McNamara D; Di Salvo T; Mathier M; Keck S; Semigran M; Dec GW
    J Heart Lung Transplant; 1996 May; 15(5):506-15. PubMed ID: 8771506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectivity of a T-cell-adapted induction therapy with anti-thymocyte globulin (Sangstat).
    Koch A; Daniel V; Dengler TJ; Schnabel PA; Hagl S; Sack FU
    J Heart Lung Transplant; 2005 Jun; 24(6):708-13. PubMed ID: 15949731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Postoperative immunosuppressive therapy for our patients with heart transplantation done in United States].
    Nunoda S; Kurosawa R; Kogashi K; Kitajima A; Momose T; Kajibashi W
    Nihon Rinsho Meneki Gakkai Kaishi; 1995 Dec; 18(6):684-8. PubMed ID: 8963786
    [No Abstract]   [Full Text] [Related]  

  • 5. Overview of tacrolimus-based immunosuppression after heart or lung transplantation.
    Reichenspurner H
    J Heart Lung Transplant; 2005 Feb; 24(2):119-30. PubMed ID: 15701425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolutionary experience with immunosuppression in pediatric intestinal transplantation.
    Bond GJ; Mazariegos GV; Sindhi R; Abu-Elmagd KM; Reyes J
    J Pediatr Surg; 2005 Jan; 40(1):274-9; discussion 279-80. PubMed ID: 15868597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mannose-binding lectin deficiency offers protection from acute graft rejection after heart transplantation.
    Fildes JE; Shaw SM; Walker AH; McAlindon M; Williams SG; Keevil BG; Yonan N
    J Heart Lung Transplant; 2008 Dec; 27(12):1353-6. PubMed ID: 19059118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolving immunosuppressive regimens for lung transplant recipients.
    Meyer NJ; Bhorade SM
    Semin Respir Crit Care Med; 2006 Oct; 27(5):470-9. PubMed ID: 17072795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress in cardiac transplantation.
    Mckenzie FN; Heimbecker RO
    Rinsho Kyobu Geka; 1982; 2(2):301-2. PubMed ID: 6760356
    [No Abstract]   [Full Text] [Related]  

  • 10. [Immunosuppressive guidelines. The differences and advantages].
    Arizón del Prado JM
    Rev Esp Cardiol; 1995; 48 Suppl 7():71-6. PubMed ID: 8775820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From clinical trials to clinical practice: an overview of Certican (everolimus) in heart transplantation.
    Valantine H; Zuckermann A
    J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S185-90; discussion S210-1. PubMed ID: 15774320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Airway anastomosis complications in de novo lung transplantation with sirolimus-based immunosuppression.
    Groetzner J; Kur F; Spelsberg F; Behr J; Frey L; Bittmann I; Vogeser M; Ueberfuhr P; Meiser B; Hatz R; Reichart B;
    J Heart Lung Transplant; 2004 May; 23(5):632-8. PubMed ID: 15135383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The incidence of acute cellular rejection after lung transplantation: a comparative study of anti-thymocyte globulin and daclizumab.
    Burton CM; Andersen CB; Jensen AS; Iversen M; Milman N; Boesgaard S; Arendrup H; Eliasen K; Carlsen J
    J Heart Lung Transplant; 2006 Jun; 25(6):638-47. PubMed ID: 16730569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoral conversion study: shift from Sandimmune classic formulation to Sandimmune Neoral in heart and lung transplant patients.
    Svendsen U; Larsen K; Allermand H; Thayssen P; Jensen S; Pettersson G
    Transplant Proc; 1995 Dec; 27(6):3477. PubMed ID: 8540057
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunologic basis of allograft rejection and immunosuppressive agents in intestinal transplantation.
    Vianna R
    Minerva Pediatr; 2009 Jun; 61(3):293-303. PubMed ID: 19461573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spectrum of susceptibility to rejection of heart and multivisceral small bowel allografts using leflunomide immunosuppression.
    D'Silva M; DeRoover A; Nishimura Y; Antoniou E; Candinas D; Hubscher SG; McMaster P
    Transplant Proc; 1996 Apr; 28(2):948-9. PubMed ID: 8623475
    [No Abstract]   [Full Text] [Related]  

  • 17. [Heart and heart-lung transplantation. Experience at the Clínica Universitaria de Navarra].
    Herreros J; Arcas R; Llorens R; Ponz L; Sáenz de Buruaga JD; Alegría E; Barba J; Martínez Caro D
    Rev Esp Cardiol; 1987; 40 Suppl 2():101-6. PubMed ID: 3137648
    [No Abstract]   [Full Text] [Related]  

  • 18. Progressive change in tolerance mechanisms after withdrawing combination immunosuppression with cyclosporine and rapamycine or leflunomide.
    Lin Y; Waer M
    Transplant Proc; 1996 Dec; 28(6):3159. PubMed ID: 8962224
    [No Abstract]   [Full Text] [Related]  

  • 19. Progress in heart transplantation.
    Wong BW; Rahmani M; Rezai N; McManus BM
    Cardiovasc Pathol; 2005; 14(4):176-80. PubMed ID: 16009314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Combined heart-lung transplantation in the Japanese monkey].
    Yoshitake T; Suzuki Y; Furuse A; Matsumoto H; Matsunaga H; Kawauchi M; Matison M; Yokoi Y; Nakajima K; Oka T
    Kyobu Geka; 1987 Feb; 40(3):192-8. PubMed ID: 3108559
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.